Appeal No. 2007-0531 Page 8
Application No. 10/341,679
into the vasculature and the heart. Page 2414, first column,
main body, first paragraph.
2. “direct intramyocardial injection of replication-deficient
adenovirus can program recombinant gene expression in the
cardiomyocytes of a large animal species with relevance to
human physiology.” Page 2414, second column, “Conclusions”
section.
3. “[r]ecombinant vectors based on adenovirus serotype 5 (Ad5)
represent an alternative means of introducing genes into the
cardiovascular system.” Page 2414, second column, main
body, first indented paragraph.
4. an experiment wherein ten injections of a replication-deficient
adenovirus vector construct were made at 2.5-mm intervals in
the anterolateral wall of the left ventricle, catheters were placed
and the incision was closed. Page 2416, first column, first full
paragraph.
5. “[r]eplication-deficient Ad5 vectors are capable of mediating
recombinant gene expression after direct injection into adult
porcine myocardium.” Pages 2420-2421, bridging paragraph.
French does not teach:
1. replication-deficient adenoviral constructs comprising
VEGF121.
Tischer teaches:
1. unlike longer forms of VEGF (e.g., VEGF165), human VEGF121
does not bind heparin. Column 2, lines 55-57.
2. “[t]he absence of heparin binding affinity [on VEGF121] leaves
more of the protein free to bind to vascular endothelial cell
growth factor receptor and increases the half-life and distribution
of the protein in circulation.” Column 2, lines 57-61.
3. VEGF “can be applied to inner vascular surfaces by systemic or
local intravenous application either as intravenous bolus
injection or infusions. If desired, . . . [VEGF] can be
administered over time using a micrometering pump.” Column
12, lines 53-57.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013